Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.

Autor: Griffin NE; Washington University School of Medicine in St Louis, St. Louis, MO, USA., Buchanan TR; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Smith SH; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Leon AA; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Meyer MF; Washington University School of Medicine in St Louis, St. Louis, MO, USA., Liu J; Division of Public Health Sciences, Washington University, St. Louis, MO, USA., Tabak RG; Institute for Public Health and Washington University, St. Louis, MO, USA., Fuh KC; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Thaker PH; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Powell MA; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Mutch DG; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Massad LS; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA., Colditz GA; Institute for Public Health and Washington University, St. Louis, MO, USA; Department of Surgery, Washington University, St. Louis, MO, USA., Hagemann AR; Division of Gynecologic Oncology, Washington Universiy, St. Louis, MO, USA. Electronic address: hagemanna@wustl.edu.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2020 Jan; Vol. 156 (1), pp. 140-146. Date of Electronic Publication: 2019 Nov 25.
DOI: 10.1016/j.ygyno.2019.11.005
Abstrakt: Objective: Cascade genetic testing (CGT) of hereditary breast and ovarian cancer (HBOC) or Lynch Syndrome (LS) patients' relatives offers opportunities to prevent cancer, but CGT rates are not well described. We aimed to measure reported disclosure of genetic testing results and CGT rates in these families and evaluate patients' views of educational media.
Methods: Patients with HBOC or LS identified from germline genetic testing at an academic institution between 2011 and 2016 were surveyed regarding disclosure, testing among relatives, and perceptions of educational materials. Medical records and pedigrees provided numbers of total and first-degree relatives.
Results: Of 103 mutation carriers consented, 64 (63%) completed the survey an average of 38 months after receiving genetic testing results. Participants' mean age was 53 years, and thirty-one (48%) had a cancer diagnosis. The majority (86%) felt extremely or very comfortable sharing health information. Participants disclosed results to 87% of first-degree relatives, but reported that only 40% of first-degree relatives underwent testing. First-degree female relatives had significantly higher CGT rates than first-degree male relatives (59% versus 21%, P < 0.001). Participants with HBOC reported higher CGT rates than those with LS (49% versus 33%, P = 0.02). Participants did not identify any one educational medium as more helpful than the others for disclosing results.
Conclusion: Disclosure rates are high among HBOC and LS mutation carriers, but reported CGT rates are low. Gender- and mutation-specific barriers prevent patients' family members from undergoing CGT. Future studies should implement materials to address these barriers and improve CGT rates.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: